ReviewCancers2021
Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Tumor-Derived Extracellular Vesicles in Plasma for Predicting Anti-PD-1 Antibody Efficacy in Non-Small Cell Lung Cancer.Cancer science · 2026Article
- [Research Progress of TNMB Staging in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Self-Normalizing Multi-Omics Neural Network for Pan-Cancer Prognostication.International journal of molecular sciences · 2025Article
- Article
- Long-Term Exposure to Real-Life Polyethylene Terephthalate Nanoplastics Induces Carcinogenesis In Vitro.Environmental science & technology · 2025Article
- A bioinformatics exploration of lung adenocarcinoma identifies hub genes with prognostic significance: from data to discovery.Journal of the Egyptian National Cancer Institute · 2025Article
- Clinical Validation of a Targeted RNA-Sequencing Assay for Driver Gene Alteration Detection in Non-Small Cell Lung Cancer.Molecular diagnosis & therapy · 2025Article
- From gene modules to gene markers: an integrated AI-human approach selects CD38 to represent plasma cell-associated transcriptional signatures.Frontiers in medicine · 2025Article
- Computational molecular insights into ibrutinib as a potent inhibitor of HER2-L755S mutant in breast cancer: gene expression studies, virtual screening, docking, and molecular dynamics analysis.Frontiers in molecular biosciences · 2025Article
- Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer.International journal of molecular sciences · 2024Article
- Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications.Molecular oncology · 2024Article
- Clinical Utility of the 31-Gene Expression Profile Test on the Management of Cutaneous Melanoma by Nurse Practitioners and Physician Assistants.Journal of the advanced practitioner in oncology · 2023Article
- Transcriptional profiling of molecular pathways allows for the definition of robust lung squamous cell carcinoma molecular subtypes with specific vulnerabilities.Clinical and translational medicine · 2023Article
- Systematic analysis of transcriptome signature for improving outcomes in lung adenocarcinoma.Journal of cancer research and clinical oncology · 2023Article
- Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines.BMC genomics · 2023Article
- Review
- Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma.Computational and structural biotechnology journal · 2022Article
- The Intriguing Thyroid Hormones-Lung Cancer Association as Exemplification of the Thyroid Hormones-Cancer Association: Three Decades of Evolving Research.International journal of molecular sciences · 2021Review
- Gene expression profiling of ovarian cancer reveals candidate diagnostic and prognostic biomarkers: An integrated bioinformatics approach.Cancer biomarkers : section A of Disease markersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Recent technological advances and the application of high-throughput mutation and transcriptome analyses have improved our understanding of cancer diseases, including non-small cell lung cancer. For instance, genomic profiling has allowed the identification of mutational events which can be treated with specific agents. However, detection of DNA alterations does not fully recapitulate the complexity of the disease and it does not allow selection of patients that benefit from chemo- or immunotherapy. In this context, transcriptional profiling has emerged as a promising tool for patient stratification and treatment guidance. For instance, transcriptional profiling has proven to be especially useful in the context of acquired resistance to targeted therapies and patients lacking targetable genomic alterations. Moreover, the comprehensive characterization of the expression level of the different pathways and genes involved in tumor progression is likely to better predict clinical benefit from different treatments than single biomarkers such as PD-L1 or tumor mutational burden in the case of immunotherapy. However, intrinsic technical and analytical limitations have hindered the use of these expression signatures in the clinical setting. In this review, we will focus on the data reported on molecular classification of non-small cell lung cancer and discuss the potential of transcriptional profiling as a predictor of survival and as a patient stratification tool to further personalize treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.